Full metal jackets (≥60 mm) of drug-eluting stents: Short- and long-term clinical and angiographic outcomes

Korean Circulation Journal

Volumn 38, Issue 2, 2008, Pages 87-94

  Sun, Hwa Lee ^a   Chae, Jei Keon ^a   Lee, Kang Hyu ^a   Lee, Sang Rok ^a   Rhee, Kyoung Suk ^a   Kim, Won Ho ^a   Ko, Jae Ki ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Drug Eluting stents; Percutaneous transluminal coronary angioplasty

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ASSESSMENT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; DRUG USE; FEMALE; FOLLOW UP; FRACTURE; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICAL RESEARCH; OCCLUSION; OUTCOME ASSESSMENT; POPULATION; PRESCRIPTION; RESTENOSIS; REVASCULARIZATION; SAFETY; THROMBOSIS; UNIVERSITY HOSPITAL;

EID: 41349116765     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2008.38.2.87     Document Type: Article

References (26)

1. Kobayashi Y, De Gregorio J, Kobayashi N, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999;34:651-9.
2. Aoki J, Ong AT, Rodriguez Granillo GA, et al. "ull metal jacket" (stented length ≥64 mm) using drug-eluting stents for de novo coronary artery lesions. Am Heart J 2005;150:994-9.
3. Kim BK, Oh S, Jeon DW, et al. Clinical outcomes following sirolimus-eluting stent implantation in patients with end-stage renal disease. Korean Circ J 2006;36:424-30.
4. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in an native coronary artery. N Engl J Med 2003;349:1315-23.
5. Dawkins KD, Grube E, Guagliumi G, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-13.
6. Degertekin M, Arampatzis CA, Lemos PA, et al. Very long sirolimus-eluting stent implantation for de novo coronary lesions. Am J Cardiol 2004;93:826-9.
7. Park JS, Kim YJ, Shin DG, et al. Clinical and angiographic outcome of sirolimus-eluting stent for the treatment of very long lesions. Korean Circ J 2006;36:490-4.
8. Lee CW, Park KH, Kim YH, et al. Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions. Am J Cardiol 2006;98:918-22.
9. Kim W, Jeong MH, Cho JY, et al. The preventive effect on in-stent restenosis of overlapped drug-eluting stents for treating diffuse coronary artery disease. Korean Circ J 2006;36:17-23.
10. Tsagalou E, Chieffo A, Iakovou I, et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 2005;45:1570-3.
11. Jaffe R, Strauss BH. Late and very late thrombosis of drug-eluting stent. J Am Coll Cardiol 2007;50:119-27.
12. Stene GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
13. Wilson GJ, Polovick JE, Huibregtse BA, Poff BC. Overlapping paclitaxel-eluting stents: long-term effects in a porcine coronary artery model. Cardiovasc Res 2007;76:361-72.
14. Finn AV, Nakazawa G, Joner M, et al. Vascular response to drug-eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-10.
15. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
16. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcomes. Circulation 1999;100:1872-8.
17. Pinto Slottow TL, Waksman R. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc Interv 2007;69:1064-74.
18. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percu taneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Circulation 1988;78:486-502.
19. Lee CW, Park SJ. Predictive factors for restenosis after drug-eluting stent implantation. Korean Circ J 2007;37:97-102.
20. Serruys PW, Foley DP, Suttorp M, et al. A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions: final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study. J Am Coll Cardiol 2002;39:393-9.
21. Kang WC, Shin EK. Treatment of diffuse long coronary artery disease with overlapping drug-eluting stents is effective? Korean Circ J 2006;36:8-10.
22. Das P, Moliterno DJ, Charnigo R, et al. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J Invasive Cardiol 2006;18:405-8.
23. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68.
24. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-54.
25. Lee MS, Jurewitz D, Argon J, Forrester J, Makkar RR, Kar S. Stent fracture associated with drug-eluting stents: clinical characteristics and implications. Catheter Cardiovasc Interv 2007;69:387-94.
26. Aoki J, Nakazawa G, Tanabe K, et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv 2007;69:380-6.